Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in c...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Josefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, Jun Guo, Hanine Rafidi, Danielle Mandikian, Yonglian Sun, Zhonghua Lin, Kellen Schneider, Pamela Zhang, Rajesh Vij, Danielle Sharpnack, Pamela Chan, Cecile de la Cruz, Jack Sadowsky, Dhaya Seshasayee, James T. Koerber, Thomas H. Pillow, Gail D. Phillips, Rebecca K Rowntree, C. Andrew Boswell, Katherine R. Kozak, Andrew G. Polson, Paul Polakis, Shang-Fan Yu, Peter S. Dragovich, Nicholas J. Agard
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis Group 2021-01-01
Edice:mAbs
Témata:
Antibody-drug conjugate
Ly6E
virus-like particles
ADC resistance
antibody discovery
On-line přístup:https://www.tandfonline.com/doi/10.1080/19420862.2020.1862452
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky